165 related articles for article (PubMed ID: 19429836)
1. Optimizing the start time of statin therapy for patients with diabetes.
Denton BT; Kurt M; Shah ND; Bryant SC; Smith SA
Med Decis Making; 2009; 29(3):351-67. PubMed ID: 19429836
[TBL] [Abstract][Full Text] [Related]
2. Do people with diabetes need statins?
White JR
Diabetes Educ; 2008; 34(4):664-73. PubMed ID: 18669808
[TBL] [Abstract][Full Text] [Related]
3. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
Jones PH
Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
[TBL] [Abstract][Full Text] [Related]
4. Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study.
Heintjes EM; Penning-van Beest FJ; Johansson S; Stalenhoef AF; Herings RM
Curr Med Res Opin; 2009 Nov; 25(11):2621-9. PubMed ID: 19743959
[TBL] [Abstract][Full Text] [Related]
5. Comparison of three different methods of assessing cardiovascular disease risk in New Zealanders with Type 2 diabetes mellitus.
Metcalf PA; Wells S; Scragg RK; Jackson R
N Z Med J; 2008 Sep; 121(1281):49-57. PubMed ID: 18797484
[TBL] [Abstract][Full Text] [Related]
6. Preventing coronary heart disease and stroke with aggressive statin therapy in older adults using a team management model.
Mason CM
J Am Acad Nurse Pract; 2009 Jan; 21(1):47-53. PubMed ID: 19125895
[TBL] [Abstract][Full Text] [Related]
7. Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial.
Weymiller AJ; Montori VM; Jones LA; Gafni A; Guyatt GH; Bryant SC; Christianson TJ; Mullan RJ; Smith SA
Arch Intern Med; 2007 May; 167(10):1076-82. PubMed ID: 17533211
[TBL] [Abstract][Full Text] [Related]
8. Deficiencies of cardiovascular risk prediction models for type 1 diabetes.
Zgibor JC; Piatt GA; Ruppert K; Orchard TJ; Roberts MS
Diabetes Care; 2006 Aug; 29(8):1860-5. PubMed ID: 16873793
[TBL] [Abstract][Full Text] [Related]
9. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
Stewart RA
Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
[TBL] [Abstract][Full Text] [Related]
10. Statin therapy in patients with type 2 diabetes.
Lo V; Noviasky J; Nashelsky J
Am Fam Physician; 2005 Sep; 72(5):866-8. PubMed ID: 16156346
[No Abstract] [Full Text] [Related]
11. UKPDS-modelling of cardiovascular risk assessment and lifetime simulation of outcomes.
Adler AI
Diabet Med; 2008 Aug; 25 Suppl 2():41-6. PubMed ID: 18717978
[TBL] [Abstract][Full Text] [Related]
12. Adherence with statins over 8 years in a usual care setting.
Vinker S; Shani M; Baevsky T; Elhayany A
Am J Manag Care; 2008 Jun; 14(6):388-92. PubMed ID: 18554077
[TBL] [Abstract][Full Text] [Related]
13. [Statins with a perspective of lifelong therapy].
Ertaş FS
Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():29-36. PubMed ID: 19404048
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study.
Zhao SP; Peng DQ; Yu BL; Huo Y;
Am Heart J; 2009 Oct; 158(4):509-512.e1. PubMed ID: 19781407
[TBL] [Abstract][Full Text] [Related]
15. Effect of statin adherence on cerebrovascular disease in primary prevention.
Perreault S; Ellia L; Dragomir A; Côté R; Blais L; Bérard A; Lalonde L
Am J Med; 2009 Jul; 122(7):647-55. PubMed ID: 19559167
[TBL] [Abstract][Full Text] [Related]
16. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease.
Faergeman O; Holme I; Fayyad R; Bhatia S; Grundy SM; Kastelein JJ; LaRosa JC; Larsen ML; Lindahl C; Olsson AG; Tikkanen MJ; Waters DD; Pedersen TR;
Am J Cardiol; 2009 Aug; 104(4):459-63. PubMed ID: 19660594
[TBL] [Abstract][Full Text] [Related]
17. Long-term adherence to statin treatment in diabetes.
Donnelly LA; Doney AS; Morris AD; Palmer CN; Donnan PT
Diabet Med; 2008 Jul; 25(7):850-5. PubMed ID: 18644071
[TBL] [Abstract][Full Text] [Related]
18. [Lipid control in diabetic patients in Extremadura (Spain)].
Roberto Robles N; Barroso S; Marcos G; Sánchez Muñoz-Torrero JF;
Endocrinol Nutr; 2009 Mar; 56(3):112-7. PubMed ID: 19627723
[TBL] [Abstract][Full Text] [Related]
19. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use.
Fraunfelder FW; Richards AB
Ophthalmology; 2008 Dec; 115(12):2282-5. PubMed ID: 18930555
[TBL] [Abstract][Full Text] [Related]
20. Lipid-lowering treatment for all could substantially reduce the burden of macrovascular complications of diabetes patients in the Netherlands.
Jacobs-van der Bruggen MA; Engelfriet PM; Hoogenveen RT; van Baal PH; Struijs JN; Verschuren WM; Smit HA; Baan CA
Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):521-5. PubMed ID: 18830084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
